^
Association details:
| Biomarker: | EGFR wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tevimbra (tislelizumab-jsgr) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A single-arm, multicenter clinical study of tislelizumab combined with chemotherapy for the treatment of driver gene-negative advanced NSCLC with bone metastasis
Excerpt:
......
Trial ID:
Source:
Title:
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Excerpt:
...Enrollment will be limited to patients with SCLC, EGFRwt NSCLC, HNSCC, mCRPC, ESCC, HER2-negative breast cancer, HER2-negative gastric cancer, colorectal cancer, ovarian cancer, endometrial cancer, cervical cancer, extrapulmonary small cell carcinoma, and soft tissue sarcoma, considering B7H3 expression and clinical data evidence. ...
Trial ID:
More C2 evidence
Source:
Title:
A prospective randomized-controlled phase II clinical study of PD-1 inhibitors combined with statins in the treatment of newly diagnosed driver gene negative advanced or metastatic NSCLC and related mechanisms
Excerpt:
...EGFR wild-type, and ALK and ROS1 fusion gene negative 4. ...
Trial ID:
Less C2 evidence
Source:
Title:
The Safety and Efficacy of Induction Chemoimmunotherapy Followed by Radiotherapy and Consolidation Immunotherapy in Locally Advanced NSCLC
Published date:
08/08/2023
Excerpt:
Patients with previously untreated, unresectable, pathologically and radiologically confirmed stage III NSCLC, EGFR/ALK-wild-type, with measurable disease were included. Patients received 3 cycles of carboplatin, paclitaxel (squamous NSCLC) or pemetrexed (non-squamous NSCLC), and tislelizumab, followed by standard thoracic radiotherapy. Patients received consolidation tislelizumab up to 14 additional cycles or until intolerable adverse events....12-months PFS rate was 86.7% (95%CI, 73.8%-99.6%). Objective response rate was 86.7% (95%CI, 73.8%-99.6%), and disease control rate was 96.7% (95%CI, 89.8%-100.0%).
Source:
Title:
Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC Patients
Published date:
08/08/2023
Excerpt:
Patients aged ≥ 70 with histologically confirmed locally advanced or metastatic NSCLC, without known sensitizing EGFR mutations or ALK rearrangements were eligible for inclusion….In this updated analysis of our perspective study, TIS plus nab-paclitaxel with or without platinum as first-line treatment for elderly advanced NSCLC patients showed clinical higher ORR, DCR, meaningful PFS benefit and longer DoR, with good safety profile.
Secondary therapy:
albumin-bound paclitaxel
Source:
Title:
Clinical Outcome of Neoadjuvant of Tislelizumab Plus Chemotherapy for Chinese Locally Advanced NSCLC Patients
Published date:
08/08/2023
Excerpt:
We enrolled 24 IIB-IIIC NSCLC patients who did not harbore any EGFR, ALK and ROS-1 driver mutations were treated with Tislelizumab plus chemotherapy...After surgery, pathological response were evaluated and MPR was 37.5%, pCR was 29.2%....Tislelizumab plus chemotherapy were effective in early or locally advanced NSCLC patients as neoadjuvant treatment.
Secondary therapy:
Chemotherapy
Source:
Title:
Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer (SACTION-01 study).
Published date:
05/25/2023
Excerpt:
In this phase II trial, patients with resectable EGFR wild-type stage IIA to IIIB NSCLC were recruited to receive SBRT (24 Gy in 3 daily fractions) to the primary tumor followed by two cycles of PD-1 inhibitor tislelizumab (200 mg) plus platinum-based doublet chemotherapy (Q3W) before surgical resection....Neoadjuvant SBRT followed by immunochemotherapy yields unprecedently high MPR and pCR rates in NSCLC without EGFR mutation.
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.2023.41.16_suppl.8540
Trial ID: